Low rates of pathological complete response reported with trastuzumab deruxtecan in early breast cancer
esmo -
AI Summary: Follow‑up data show lower-than-expected pathological complete response rates with trastuzumab‑deruxtecan in the early‑stage HER2‑positive breast cancer setting, raising questions about neoadjuvant activity and optimal patient selection. These findings, discussed alongside combination strategies and decision analyses, suggest caution before declaring the antibody‑drug conjugate a neoadjuvant panacea.
Related Stories
Merck and Moderna report positive phase‑3 melanoma vaccine results / 2 months
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 2 months
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 2 months
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 2 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 3 months
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 3 months
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Eli Lilly, Neuroscience, Pancreatic Cancer, Autism and look for the RSS link.
StackHealth Time Machine